Systemic Bioavailability and Pharmacokinetics of the Doxylamine–Pyridoxine Delayed-Release Combination (Diclectin)
Authors:
- Facundo Garcia-BournissenFGFacundo Garcia-Bournissen
- Gideon KorenGKGideon Koren
- 1 February 2011
- journal article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 33 (1) , 115-119
Abstract
Diclectin, composed of 10 mg doxylamine succinate (DOX) and 10 mg pyridoxine hydrochloride, is the drug combination of choice for the management of nausea and vomiting during pregnancy in Canada. However, there is large variability in its onset and duration of action among women. To understand and improve its effectiveness, the variability in the pharmacokinetics of the ingredients in this doxylamine succinate/pyridoxine hydrochloride combination must be studied. To determine the pharmacokinetics of DOX and pyridoxine after oral administration of two tablets of this drug combination in the form of Diclectin and to calculate their respective relative bioavailability by comparison with intravenous administration in another population. Eighteen nonpregnant, nonlactating, healthy females between 18 and 45 years of age were administered two tablets of Diclectin with 240 mL of water under empty stomach conditions. Blood samples were analyzed for DOX and pyridoxine along with its four active metabolites: pyridoxal, pyridoxal-5′-phosphate (PLP), pyridoxamine, and pyridoxamine-5′-phosphate using tandem mass spectrometry. For the purpose of this study, pharmacokinetic values for DOX and PLP were adjusted for body weight. The mean DOX-AUC0→∞ was calculated to be 3137.22 ± 633.57 ng·hr/mL (range, 2056.59-4376.06 ng·hr/mL). The mean PLP-AUC0→∞ was calculated to be 5513.10 ± 2362.35 ng·hr/mL (range, 1572.56-10,153.77 ng·hr/mL). Based on literature values of the PLP-AUC0→∞ after intravenous administration and data from the current study, the relative bioavailability of pyridoxine in Diclectin was calculated at 100%. There was a 2.1-fold variability in the DOX-AUC0→∞ and 6.5-fold variability in the PLP-AUC0→∞ after oral administration of 20 mg Diclectin. Using literature values and data from the current study, we estimated the oral bioavailability of pyridoxine to be 100%. Therefore, interindividual differences in metabolism, and not in bioavailability, may be important sources of variability that need to be addressed in dosing guidelines.Keywords
This publication has 11 references indexed in Scilit:
- Treatment Options for Nausea and Vomiting During PregnancyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2006
- Diclectin Therapy for Nausea and Vomiting of Pregnancy: Effects of Optimal DosingJournal of Obstetrics and Gynaecology Canada, 2003
- The burden of illness of severe nausea and vomiting of pregnancy in the United StatesAmerican Journal of Obstetrics and Gynecology, 2002
- Nausea and vomiting in pregnancy: The problem of perception—is it really a disease?American Journal of Obstetrics and Gynecology, 2002
- The Safety of Higher Than Standard Dose of Doxylamine‐Pyridoxine (Diclectin®) for Nausea and Vomiting of PregnancyThe Journal of Clinical Pharmacology, 2001
- Factors associated with elective termination of pregnancy among Canadian and American women with nausea and vomiting of pregnancyJournal of Psychosomatic Obstetrics & Gynecology, 2001
- Nausea and vomiting in early pregnancyInternational Journal of Gynecology & Obstetrics, 1988
- Metabolism of 14C-Labeled Doxylamine Succinate (Bendectin® in the Rhesus Monkey (Macaca mulatta)*Journal of Analytical Toxicology, 1986
- Availability of vitamin B6 and pantothenate in an average American diet in manThe American Journal of Clinical Nutrition, 1981